Exelixis (EXEL) Other Accumulated Expenses (2010 - 2026)
Exelixis' (EXEL) quarterly Other Accumulated Expenses came in at $100.3 million in Q2 2026, down 20.12% year-on-year from $125.6 million in Q2 2025, and down 20.02% quarter-over-quarter from $125.4 million in Q1 2026.
Exelixis (EXEL) Other Accumulated Expenses (2010 - 2026) Analysis & Trends
Exelixis' Other Accumulated Expenses history runs 17 years deep, the most recent figure standing at $100.3 million for Q2 2026.
- On a quarterly basis, Other Accumulated Expenses fell 20.12% year-over-year to $100.3 million in Q2 2026; TTM through Apr 2026 was $100.3 million, a 20.12% decrease from a year earlier, with the FY2026 full-year figure at $125.4 million, up 31.96% from the prior year.
- Other Accumulated Expenses fell to $100.3 million in Q2 2026 per EXEL's latest filing, from $125.4 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $125.6 million in Q2 2025 and bottomed at $63.7 million in Q2 2022.
- The 5-year median for Other Accumulated Expenses is $101.4 million (2025), against an average of $99.0 million.
- Across the five-year window, Other Accumulated Expenses soared 55.39% in 2023 and retreated 23.1% in 2024, its largest moves.
- Year by year, Other Accumulated Expenses stood at $78.9 million in 2022, then surged by 37.37% to $108.4 million in 2023, then slipped by 11.71% to $95.7 million in 2024, then climbed by 9.3% to $104.6 million in 2025, then decreased by 4.14% to $100.3 million in 2026.
- Per Business Quant, the three latest EXEL Other Accumulated Expenses figures stand at $100.3 million (Q2 2026), $125.4 million (Q1 2026), and $104.6 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn |
| 10 | Exelixis | 14.47 Bn | 13.69 Bn | 590.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 100.29 Mn |
| Jan 2, 2026 | 125.38 Mn |
| Oct 3, 2025 | 104.62 Mn |
| Jul 4, 2025 | 101.37 Mn |
| Apr 4, 2025 | 125.55 Mn |
| Jan 3, 2025 | 95.01 Mn |
| Sep 27, 2024 | 95.72 Mn |
| Jun 28, 2024 | 103.24 Mn |
| Mar 29, 2024 | 104.29 Mn |
| Dec 29, 2023 | 108.42 Mn |
| Sep 29, 2023 | 124.48 Mn |
| Jun 30, 2023 | 110.70 Mn |
| Mar 31, 2023 | 89.49 Mn |
| Dec 30, 2022 | 78.92 Mn |
| Sep 30, 2022 | 80.11 Mn |
| Jul 1, 2022 | 72.57 Mn |
| Apr 1, 2022 | 63.65 Mn |
| Dec 31, 2021 | 53.37 Mn |
| Oct 1, 2021 | 54.75 Mn |
| Jul 2, 2021 | 63.85 Mn |